Navigation Links
OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
Date:3/4/2010

BOTHELL, WA and VANCOUVER, WA, March 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and fiscal year 2009 financial results will be released at the market close on Monday, March 8, 2010, and that the Company will host a conference call and live webcast at 4:30 p.m. EDT that afternoon. Management will discuss the company's financial results and provide a 2010 corporate outlook.

A live webcast will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at http://ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-604-9670 (U.S. & Canada) or 719-325-4746 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, OGX-011. The companies expect to initiate two Phase 3 trials in castrate resistant prostate cancer in 2010, and a third Phase 3 trial in non-small cell lung cancer in early 2011; OGX-427 is in Phase 1 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

More information about OncoGenex is available at www.oncogenex.com.

SOURCE OncoGenex Pharmaceuticals, Inc.

Back to top
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
2. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
3. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
4. OncoGenex Reports Third Quarter 2009 Financial Results
5. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
7. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
8. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
9. OncoGenex Reports Second Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... L3 ... to announce the company is now a certified iMedNet eClinical and Electronic Data ... enables the company’s clinical research team to build, customize and manage clinical trial ...
(Date:4/24/2017)... Yorba Linda, Ca (PRWEB) , ... April 24, ... ... can protect proteins from thermal denaturation in a cellular milieu; however, the broad ... by a lack of simple platforms with sensitive quantitative readouts. Cell-based thermal stabilization ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... related applications were the focus of researchers, engineers, product developers, and industry suppliers ... Anaheim. , Sponsored by SPIE, the international society for optics and photonics ...
(Date:4/20/2017)... ... April 20, 2017 , ... Assured ... partnership to offer a full spectrum of digital security goods and services. The ... products and the ground-breaking proactive cybersecurity services and products through Assured Enterprises. The ...
Breaking Biology Technology:
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):